This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. A fresh Q1 is underway, your meetings at JPMorgan were top notch, and you have a

Yesterday Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. With only a few hundred patients ever treated with their therapies, $20B represents a lot of promise in

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Biotech newsflow came out the gate a little slow in 2018 (though it appears it may be speeding up

As 2018 begins, and we prepare for the biopharma sector’s annual kickoff in San Francisco next week, my thoughts are focused on the snow. I’m literally watching bombogenesis unleash a blizzard white-out in Boston right now. As a winter sports

Heading into the winter holidays always brings out festive reflections of the past year. Twelve months ago, we were thrilled to say goodbye to 2016 and excited to embrace 2017’s promise.  And in large part, the past year has delivered

Four years ago, in December 2013, I highlighted Atlas’ seed-led venture creation model by walking through our Fund IX Seed Class of 2013.  Only a short 1400 days ago, reading it again last week made it seem like an eternity.

This blog was written by Mike Gilman, CEO of Obsidian Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC. Consider the leech – the first living medicine. In its heyday in the 19th century –

It’s been an exciting year for new drug approvals, with the FDA on a similar pace to the gangbuster year of 2015. Many of these new medicines address significant and meaningful needs, or offer additional therapeutic choices for patients and

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On June 27, 2016 England’s soccer team was knocked out of the European Championships by Iceland – a tiny

Back in the summer, I got the call that no biotech venture investor wants to get. On the morning of August 8th, I received an urgent text of “can you talk now?” quickly followed with a call. I learned then

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell

The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies. The “druggable genome” historically included intracellular catalytic proteins, (e.g., enzymes